{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T21:49:55Z","timestamp":1753739395751,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Aminoglycosides are crucial for treating multidrug-resistant gram-negative infections and endocarditis. However, aminoglycosides are associated with significant risks of nephrotoxicity, necessitating careful dose selection and therapeutic drug monitoring. Therapeutic drug monitoring is essential for minimizing risk; however, few institutions routinely perform it. This study aimed to assess the impact of a pharmacist-driven therapeutic drug monitoring intervention on aminoglycoside usage trends and clinical outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study included 263 patients treated with aminoglycosides between 2014 and 2023. A pharmacist-led therapeutic drug monitoring intervention began in 2017, focusing on monitoring renal function, documenting patient weight, and closely managing aminoglycoside concentrations. Trends in aminoglycoside use and renal outcomes were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Over the study period, appropriate use of aminoglycosides at the time of initial prescription increased from 49 to 82% (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Pharmacist dosing design at initial prescription increased significantly from 21% pre-intervention to 60% post-intervention (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). The proportion of pharmacist intervention in initial dosing design increased over time. The proportion of patients with measured aminoglycoside blood concentrations significantly increased from 53% pre-intervention to 72% post-intervention (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). The proportion of patients who were able to manage target blood concentrations from the initial aminoglycoside dose without dose adjustments increased from 31% pre-intervention to 42% post-intervention, although the results were not significantly different (<jats:italic>P<\/jats:italic>\u2009=\u20090.07). The incidence rate of renal impairment remained similar (11% vs. 12%; <jats:italic>P<\/jats:italic>\u2009=\u20090.85), although the annual average number of cases decreased from 4.3 before the intervention to 2.5 after. Similarly, there were no significant differences in clinical efficacy before and after the intervention (65% vs. 71%; <jats:italic>P<\/jats:italic>\u2009=\u20090.35). Furthermore, aminoglycoside stewardship led to a 56% cost saving.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Pharmacist-led aminoglycoside stewardship significantly improved the appropriate use of aminoglycosides and decreased the associated costs. Thus, pharmacist involvement is essential for the proper use of aminoglycosides. However, many patients required aminoglycoside dose reductions despite the pharmacist\u2019s guideline-based dosing design. Therefore, further accumulation of information on the management of aminoglycoside blood concentration may be necessary for the revision of these guidelines.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-024-00399-x","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T16:36:22Z","timestamp":1732811782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of pharmacist-led aminoglycoside stewardship: a 10-year observational study"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2350-9227","authenticated-orcid":false,"given":"Yasutaka","family":"Shinoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7105-7982","authenticated-orcid":false,"given":"Kengo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiseki","family":"Usami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"399_CR1","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1253\/circj.CJ-19-0549","volume":"83","author":"S Nakatani","year":"2019","unstructured":"Nakatani S, Ohara T, Ashihara K, Izumi C, Iwanaga S, Eishi K, et al. JCS 2017 guideline on prevention and treatment of infective endocarditis. Circ J. 2019;83:1767\u2013809. https:\/\/doi.org\/10.1253\/circj.CJ-19-0549.","journal-title":"Circ J"},{"key":"399_CR2","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","volume":"44","author":"V Delgado","year":"2023","unstructured":"Delgado V, Ajmone Marsan N, De Waha S, Bonaros N, Brida M, Burri H, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023;44:3948\u20134042. https:\/\/doi.org\/10.1093\/eurheartj\/ehad193.","journal-title":"Eur Heart J"},{"key":"399_CR3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1469-0691.2007.01681.x","volume":"13","author":"N Mesaros","year":"2007","unstructured":"Mesaros N, Nordmann P, Pl\u00e9siat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect. 2007;13:560\u201378. https:\/\/doi.org\/10.1111\/j.1469-0691.2007.01681.x.","journal-title":"Clin Microbiol Infect"},{"key":"399_CR4","doi-asserted-by":"publisher","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis Infect Dis Soc Am. 2023;ciad428. https:\/\/doi.org\/10.1093\/cid\/ciad428.","DOI":"10.1093\/cid\/ciad428"},{"key":"399_CR5","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.3390\/jcm10194594","volume":"10","author":"A Marino","year":"2021","unstructured":"Marino A, Munaf\u00f2 A, Zagami A, Ceccarelli M, Di Mauro R, Cantarella G, et al. Ampicillin plus ceftriaxone regimen against Enterococcus faecalis endocarditis: a literature review. J Clin Med. 2021;10:4594. https:\/\/doi.org\/10.3390\/jcm10194594.","journal-title":"J Clin Med"},{"key":"399_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ijantimicag.2010.11.029","volume":"37","author":"R Marcus","year":"2011","unstructured":"Marcus R, Paul M, Elphick H, Leibovici L. Clinical implications of \u03b2-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents. 2011;37:491\u2013503. https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.11.029.","journal-title":"Int J Antimicrob Agents"},{"key":"399_CR7","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1128\/AAC.01430-08","volume":"53","author":"JFP Oliveira","year":"2009","unstructured":"Oliveira JFP, Silva CA, Barbieri CD, Oliveira GM, Zanetta DMT, Burdmann EA. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2009;53:2887\u201391. https:\/\/doi.org\/10.1128\/AAC.01430-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"399_CR8","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00467-016-3533-z","volume":"32","author":"SJ McWilliam","year":"2017","unstructured":"McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M. Aminoglycoside-induced nephrotoxicity in children. Pediatr Nephrol. 2017;32:2015\u201325. https:\/\/doi.org\/10.1007\/s00467-016-3533-z.","journal-title":"Pediatr Nephrol"},{"key":"399_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.taap.2007.05.004","volume":"223","author":"C Mart\u00ednez-Salgado","year":"2007","unstructured":"Mart\u00ednez-Salgado C, L\u00f3pez-Hern\u00e1ndez FJ, L\u00f3pez-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol. 2007;223:86\u201398. https:\/\/doi.org\/10.1016\/j.taap.2007.05.004.","journal-title":"Toxicol Appl Pharmacol"},{"key":"399_CR10","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.26355\/eurrev_202205_28868","volume":"26","author":"X Huang","year":"2022","unstructured":"Huang X, Liu YX, Lao JH, Cao J, Li X, Yao WB. The incidence of acute kidney injury in hospitalised patients receiving aminoglycoside antibiotics: a retrospective study. Eur Rev Med Pharmacol Sci. 2022;26:3718\u201325. https:\/\/doi.org\/10.26355\/eurrev_202205_28868.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"399_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jiac.2020.09.033","volume":"27","author":"T Yamada","year":"2021","unstructured":"Yamada T, Fujii S, Shigemi A, Takesue Y. A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity. J Infect Chemother. 2021;27:256\u201361. https:\/\/doi.org\/10.1016\/j.jiac.2020.09.033.","journal-title":"J Infect Chemother"},{"key":"399_CR12","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1093\/cid\/ciw118","volume":"62","author":"TF Barlam","year":"2016","unstructured":"Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62:e51\u201377. https:\/\/doi.org\/10.1093\/cid\/ciw118.","journal-title":"Clin Infect Dis"},{"key":"399_CR13","first-page":"175","volume":"65","author":"K Matsumoto","year":"2017","unstructured":"Matsumoto K, Isoda R, Kuroda Y, Kuroda Y, Yokoyama Y, Kizu J. National survey of therapeutic drug monitoring (TDM) of antimicrobial drugs: comparison with the TDM guidelines for antimicrobial drugs. Jpn J Chemother. 2017;65:175\u201382.","journal-title":"Jpn J Chemother"},{"key":"399_CR14","doi-asserted-by":"publisher","first-page":"106180","DOI":"10.1016\/j.ijantimicag.2020.106180","volume":"56","author":"S Imani","year":"2020","unstructured":"Imani S, Alffenaar JW, Cotta MO, Daveson K, van Hal S, Lau C, et al. Therapeutic drug monitoring of commonly used anti-infective agents: a nationwide cross-sectional survey of Australian hospital practices. Int J Antimicrob Agents. 2020;56:106180. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106180.","journal-title":"Int J Antimicrob Agents"},{"key":"399_CR15","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","volume":"71","author":"LD Charles","year":"2020","unstructured":"Charles LD, Jonathan ML, Christoph L, Emmanuelle C, Richard JW Jr, Claire A, Erik CB, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Clin Infect Dis. 2020;71:905\u201313.","journal-title":"Clin Infect Dis"},{"key":"399_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/599376","volume":"49","author":"LA Mermel","year":"2009","unstructured":"Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O\u2019Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1\u201345. https:\/\/doi.org\/10.1086\/599376.","journal-title":"Clin Infect Dis"},{"key":"399_CR17","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1089\/sur.2022.206","volume":"23","author":"SA Buckman","year":"2022","unstructured":"Buckman SA, Forrester JD, Bessoff KE, Parli SE, Evans HL, Huston JM. Surgical Infection Society Guidelines: 2022 updated guidelines for antibiotic use in open extremity fractures. Surg Infect (Larchmt). 2022;23:817\u201328. https:\/\/doi.org\/10.1089\/sur.2022.206.","journal-title":"Surg Infect (Larchmt)"},{"key":"399_CR18","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56\u201393. https:\/\/doi.org\/10.1093\/cid\/cir073.","journal-title":"Clin Infect Dis"},{"key":"399_CR19","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179\u201384. https:\/\/doi.org\/10.1159\/000339789.","journal-title":"Nephron Clin Pract"},{"key":"399_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transpl"},{"key":"399_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4058\/jsei.33.62","volume":"33","author":"H Katagiri","year":"2018","unstructured":"Katagiri H, Mitsuboshi S, Katagiri H, Tsugita M. Antimicrobial therapeutic drug monitoring performance rate in Niigata: evaluation between performance rate and relevant factors. Japanese J Environ Infections. 2018;33:62\u20136. https:\/\/doi.org\/10.4058\/jsei.33.62.","journal-title":"Japanese J Environ Infections"},{"key":"399_CR22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00228-014-1680-3","volume":"70","author":"L Nezic","year":"2014","unstructured":"Nezic L, Derungs A, Bruggisser M, Tschudin-Sutter S, Kr\u00e4henb\u00fchl S, Haschke M. Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy. Eur J Clin Pharmacol. 2014;70:829\u201337. https:\/\/doi.org\/10.1007\/s00228-014-1680-3.","journal-title":"Eur J Clin Pharmacol"},{"key":"399_CR23","doi-asserted-by":"publisher","first-page":"7468","DOI":"10.1128\/AAC.03750-14","volume":"58","author":"W Picard","year":"2014","unstructured":"Picard W, Bazin F, Clouzeau B, Bui HN, Soulat M, Guilhon E, et al. Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock. Antimicrob Agents Chemother. 2014;58:7468\u201374. https:\/\/doi.org\/10.1128\/AAC.03750-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"399_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00431-016-2691-0","volume":"175","author":"M Houot","year":"2016","unstructured":"Houot M, Pilmis B, Thepot-Seegers V, Suard C, Potier C, Postaire M, et al. Aminoglycoside use in a pediatric hospital: there is room for improvement-a before\/after study. Eur J Pediatr. 2016;175:659\u201365. https:\/\/doi.org\/10.1007\/s00431-016-2691-0.","journal-title":"Eur J Pediatr"},{"key":"399_CR25","doi-asserted-by":"publisher","unstructured":"Nauriyal V, Rai SM, Joshi RD, Thapa BB, Kaljee L, Prentiss T, et al. Evaluation of an antimicrobial stewardship program for wound and burn care in three hospitals in Nepal. Antibiot (Basel). 2020;9:914. https:\/\/doi.org\/10.3390\/antibiotics9120914.","DOI":"10.3390\/antibiotics9120914"},{"key":"399_CR26","doi-asserted-by":"publisher","unstructured":"Sandaradura I, Alffenaar JW, Cotta MO, Daveson K, Day RO, Van Hal S, et al. Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: availability, performance and barriers to implementation. Br J Clin Pharmacol. 2022;88:669\u201379. https:\/\/doi.org\/10.1111\/bcp.14995.","DOI":"10.1111\/bcp.14995"},{"key":"399_CR27","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ijantimicag.2014.11.006","volume":"45","author":"PP Cook","year":"2015","unstructured":"Cook PP, Gooch M. Long-term effects of an antimicrobial stewardship programme at a tertiary-care teaching hospital. Int J Antimicrob Agents. 2015;45:262\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.11.006.","journal-title":"Int J Antimicrob Agents"},{"key":"399_CR28","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/14787210.2017.1382355","volume":"15","author":"V Pitiriga","year":"2017","unstructured":"Pitiriga V, Dimitroulia E, Saroglou G, Tsakris A. The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role? Expert Rev Anti Infect Ther. 2017;15:947\u201354. https:\/\/doi.org\/10.1080\/14787210.2017.1382355.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"399_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.cmi.2019.10.017","volume":"26","author":"D Lebeaux","year":"2020","unstructured":"Lebeaux D, Fern\u00e1ndez-Hidalgo N, Pilmis B, Tattevin P, Mainardi J. Aminoglycosides for infective endocarditis: time to say goodbye? Clin Microbiol Infect. 2020;26:723\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2019.10.017.","journal-title":"Clin Microbiol Infect"},{"key":"399_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13613-021-00834-4","volume":"11","author":"C Roger","year":"2021","unstructured":"Roger C, Louart B, Elotmani L, Barton G, Escobar L, Koulenti D, et al. An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. Ann Intensive Care. 2021;11:49. https:\/\/doi.org\/10.1186\/s13613-021-00834-4.","journal-title":"Ann Intensive Care"},{"key":"399_CR31","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","volume":"43","author":"MJ Rybak","year":"1999","unstructured":"Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43:1549\u201355. https:\/\/doi.org\/10.1128\/AAC.43.7.1549.","journal-title":"Antimicrob Agents Chemother"},{"key":"399_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/00003088-200342050-00007","volume":"42","author":"F Rougier","year":"2003","unstructured":"Rougier F, Ducher M, Maurin M, Corvaisier S, Claude D, Jelliffe R, et al. Aminoglycoside dosages and nephrotoxicity: quantitative relationships. Clin Pharmacokinet. 2003;42:493\u2013500. https:\/\/doi.org\/10.2165\/00003088-200342050-00007.","journal-title":"Clin Pharmacokinet"},{"key":"399_CR33","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1093\/jac\/dkw250","volume":"71","author":"A Jenkins","year":"2016","unstructured":"Jenkins A, Thomson AH, Brown NM, Semple Y, Sluman C, MacGowan A, et al. Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. J Antimicrob Chemother. 2016;71:2754\u20139. https:\/\/doi.org\/10.1093\/jac\/dkw250.","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00399-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-024-00399-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00399-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T17:03:42Z","timestamp":1732813422000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-024-00399-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1186\/s40780-024-00399-x","relation":{},"ISSN":["2055-0294"],"issn-type":[{"type":"electronic","value":"2055-0294"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of our hospital (approval number: 202401). Comprehensive informed consent was obtained from the participants by displaying an opt-out option on our website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}